{
    "clinical_study": {
        "@rank": "80639", 
        "arm_group": [
            {
                "arm_group_label": "Dose Escalation", 
                "arm_group_type": "Experimental", 
                "description": "MK-8892 doses starting at 1 mg, are sequentially escalated, stopping at the HAT dose or a maximum of 14 mg."
            }, 
            {
                "arm_group_label": "HAT Dose", 
                "arm_group_type": "Experimental", 
                "description": "Dose of MK-8892 that is highest acutely tolerated or a maximum of 14 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial will study the safety, tolerability, and pharmacodynamics of single\n      doses of MK-8892 in participants with PAH. The primary objective is to estimate the measured\n      peak effect of the highest acutely tolerated (HAT) single oral dose of MK-8892 on pulmonary\n      vascular resistance (PVR)."
        }, 
        "brief_title": "Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  postmenopausal female or if female of reproductive potential, remains abstinent or\n             uses two acceptable methods of birth control during 14 days after  dosing with\n             MK-8892\n\n          -  has suspected PAH classified in one of the following sub-groups: idiopathic,\n             heritable, drug- or toxin-induced, or associated with connective tissue disease, as\n             defined by the Dana Point 2008 Clinical Classification\n\n          -  has a clinical indication for right heart catheterization\n\n          -  PAH classified as World Health Organization (WHO) functional class II or III\n\n        Exclusion Criteria:\n\n          -  has a medical history indicating a secondary cause of Pulmonary Hypertension (PH) or\n             a non-included etiology of PAH including the following tests within 6 months of Visit\n             1: Echo indicating significant left heart disease, valvular disease, or structural\n             defects; function test indicating significant pulmonary disease; imaging test\n             indicating veno-occlusive disease; perfusion scan indicating thromboembolic disease;\n             abdominal ultrasound indicating cirrhosis; positive test for human immunodeficiency\n             virus (HIV)\n\n          -  has persistent or permanent atrial fibrillation, significantly impaired gas exchange,\n             history of radiation of the lung or mediastinum, hepatic or hepatobiliary disease,\n             immunodeficiencies or latent bleeding risk\n\n          -  has estimated Glomerular Filtration Rate (GFR) <45 mL/min\n\n          -  has alanine aminotransferase test (ALT) serum glutamic pyruvic transaminase (SGPT) or\n             aspartate aminotransferase test (AST) serum glutamic oxaloacetic transaminase (SGOT)\n             >= 3 x upper limit of normal (ULN) at Visit 1\n\n          -  has a systolic blood pressure (BP) <105 mmHg, or heart rate (HR) > 100 beats/min at\n             Visit 1 (Day -7 to -1)\n\n          -  has previously received specific therapy for PAH within 4 weeks prior to Visit 1\n\n          -  has taken sildenafil, valdenafil or a nitrate within 24 hours prior to Visit 2 date\n\n          -  has taken tadalafil within 7 days prior to Visit 2 date\n\n          -  has taken 2 or more specific PAH medications concomitantly within 4 weeks of\n             anticipated Visit 2 date. Only treatment na\u00efve subjects or subjects on stable\n             PAH-specific monotherapy with an endothelin receptor antagonist ([ERA]; bosentan,\n             ambrisentan, or macitentan) or a prostacyclin analog ([PCA]; treprostinil,\n             epoprostenol, or iloprost) are eligible. PAH monotherapy with one of these\n             medications may continue without interruption during this study\n\n          -  has taken a soluble guanylate cyclase (sGC) activator (riociguat) within 24 hours of\n             anticipated Visit 2 date.\n\n          -  has taken diltiazem immediate release within 1 day or diltiazem extended release\n             within 2 days prior to Visit 2 date\n\n          -  is currently taking potent inhibitors or inducers of Cytochrome P450 3A4 (CYPA4), or\n             is consuming >1 liter of grapefruit juice per day\n\n          -  is pregnant or breastfeeding or expecting to conceive during study or post study\n             follow-up period\n\n          -  has donated 500 mL of blood within prior 60 days\n\n          -  is currently participating in or has within the prior three months participated in a\n             study with an investigational compound or device"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934647", 
            "org_study_id": "8892-003", 
            "secondary_id": "2013-001680-23"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose Escalation", 
                "HAT Dose"
            ], 
            "description": "Single oral capsule with up to 14 mg of MK-8892", 
            "intervention_name": "MK-8892", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "last_name": "German Medical Information Center", 
                "phone": "49 800 673 673 673"
            }, 
            "facility": {
                "address": {
                    "city": "Haar", 
                    "country": "Germany"
                }, 
                "name": "Merck Sharp & Dohme GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Peak percent reduction from baseline in PVR at the HAT single oral dose of MK-8892", 
            "safety_issue": "No", 
            "time_frame": "Baseline and up to 5 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}